Francisco Hernández-Bernal, Donner Estenoz-García, Juan H Gutiérrez-Ronquillo, Yenima Martín-Bauta, Karen Catasús-Álvarez, Mario Gutiérrez-Castillo, Marbelys Guevara-Rodríguez, Aliuska Castro-Jeréz, Yoandra Fuentes-González, Yulemis Pinto-Cruz, Carmen Valenzuela-Silva, Verena L Muzio-González, Héctor Pérez-Saad, Nelvys Subirós-Martínez, Gerardo E Guillén-Nieto, Diana Garcia-Del-Barco-Herrera
OBJECTIVE: This study tested the hypothesis that a neuroprotective combined therapy based on epidermal growth factor (EGF) and growth hormone-releasing hexapeptide (GHRP6) could be safe for acute ischemic stroke patients, admitting up to 30% of serious adverse events (SAE) with proven causality. METHODS: A multi-centric, randomized, open-label, controlled, phase I-II clinical trial with parallel groups was conducted (July 2017 to January 2018). Patients aged 18-80 years with a computed tomography-confirmed ischemic stroke and less than 12 h from the onset of symptoms were randomly assigned to the study groups I (75 μg rEGF + 3...
2024: Frontiers in Neurology